ALL ABOUT DAILYZ HEALTH NEWS
ALL ABOUT DAILYZ HEALTH NEWS
The FDA approved Pfizer’s Ibrance as maintenance therapy for HR-positive, HER2-positive metastatic breast cancer in combination with trastuzumab and endocrine therapy.
The FDA approved Pfizer’s Ibrance as maintenance therapy for HR-positive, HER2-positive metastatic breast cancer in combination with trastuzumab and endocrine therapy.
The FDA approved Pfizer’s Ibrance as maintenance therapy for HR-positive, HER2-positive metastatic breast cancer in combination with trastuzumab and endocrine therapy.
The FDA approved Pfizer’s Ibrance as maintenance therapy for HR-positive, HER2-positive metastatic breast cancer in combination with trastuzumab and endocrine therapy.
The FDA approved Pfizer’s Ibrance as maintenance therapy for HR-positive, HER2-positive metastatic breast cancer in combination with trastuzumab and endocrine therapy.
The FDA approved Pfizer’s Ibrance as maintenance therapy for HR-positive, HER2-positive metastatic breast cancer in combination with trastuzumab and endocrine therapy.
Read More
The U.S. HHS proposed clinical trial reforms to limit Chinese biotech participation and boost domestic drug development.
Read More
A major study at ENDO 2026 finds global heart disease now peaks at ages 50-54, driven by rising obesity and fastest growth in South Asia.
Read More
GLP-1 drugs like semaglutide linked to 15% lower fracture risk and greater weight loss in type 2 diabetes patients versus other obesity medications.
Read More
A study at ENDO 2026 found that type 2 diabetes patients who nap over 30 minutes have a higher risk of fatty liver disease.
Read More
Bangladesh’s measles outbreak has killed over 650 children, prompting WHO and UNICEF to launch emergency vaccinations for young children.
Read More
The FDA approved CASGEVY™, the first CRISPR gene-edited cell therapy, for severe sickle cell disease patients 12 and older with recurrent crises.
Read More
The WHO has not declared a global health emergency over the drug-resistant tuberculosis strain linked to U.S. travelers as of mid-2025.
Read More
The Biden administration announced a plan to cap insulin out-of-pocket costs at $35 monthly for all insured Americans, expanding beyond Medicare.
Read More
As of mid-2026, the FDA has not approved any gene-editing therapies for type 1 diabetes, with such treatments still in preclinical stages.
Read More
